We first treated Du145 prostate cancer (PCa) cells with two clinical drugs, i.e., etoposide (VP16) and paclitaxel (Taxol) as well as three experimental drugs, staurosporine (STS), a promiscuous protein kinase inhibitor, and two newly synthesized paclitaxel analogs termed WP1102 and WP1103 (details to be presented elsewhere). The gene discussed is WEE1; the disease is posterior cortical atrophy.